Effect of impaired kidney function on outcomes and treatment effects of oral anticoagulant regimes in patients with atrial fibrillation in a real-world registry
The impact of impaired kidney function on outcomes and treatment benefits of vitamin-K antagonists (VKA) versus direct oral anticoagulants (DOAC) in patients with atrial fibrillation (AF) has insufficiently been investigated in randomized controlled studies (RCTs). Most studies and registries are ei...
Saved in:
| Published in | PloS one Vol. 19; no. 9; p. e0310838 |
|---|---|
| Main Authors | , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
United States
Public Library of Science
23.09.2024
|
| Subjects | |
| Online Access | Get full text |
| ISSN | 1932-6203 1932-6203 |
| DOI | 10.1371/journal.pone.0310838 |
Cover
| Abstract | The impact of impaired kidney function on outcomes and treatment benefits of vitamin-K antagonists (VKA) versus direct oral anticoagulants (DOAC) in patients with atrial fibrillation (AF) has insufficiently been investigated in randomized controlled studies (RCTs). Most studies and registries are either biased due to incomplete enrolment of consecutive patients in large pharma industry sponsored registries, or due to short recruitment periods or incomplete assessment of important variables in national registries.
This study uses data from the Heidelberg Registry of Atrial Fibrillation (HERA-FIB), a retrospective single-center registry of 10,222 consecutive patients with AF presenting to the emergency department of University Hospital of Heidelberg from June 2009 until March 2020. Rates of all-cause mortality, stroke, major bleeding and myocardial infarction (MI) were related to the presence and severity of impaired presenting kidney function, as well as to assigned treatment with VKA vs. DOAC.
The risks for all-cause mortality (HR: 3.26, p<0.001), stroke (HR: 1.58, p<0.001), major bleeding (HR: 2.28, p<0.001) and MI (HR: 2.48, p<0.001) were significantly higher in patients with an eGFR<60 ml/min at admission and increased with decreasing eGFR. After adjustment for variables of CHA2DS2VASc-score, presence of eGFR <60 ml/min remained as an independent predictor for all-cause mortality, major bleeding and MI. The hazard ratio (HR) for all-cause mortality, major bleedings and MI was significantly lower in patients receiving DOAC compared to VKA.
Findings from our large real-life registry confirm the data from RCTs and extend our knowledge on the effectiveness and safety of DOACs to subjects that were underrepresented in RCTs. |
|---|---|
| AbstractList | BackgroundThe impact of impaired kidney function on outcomes and treatment benefits of vitamin-K antagonists (VKA) versus direct oral anticoagulants (DOAC) in patients with atrial fibrillation (AF) has insufficiently been investigated in randomized controlled studies (RCTs). Most studies and registries are either biased due to incomplete enrolment of consecutive patients in large pharma industry sponsored registries, or due to short recruitment periods or incomplete assessment of important variables in national registries.MethodsThis study uses data from the Heidelberg Registry of Atrial Fibrillation (HERA-FIB), a retrospective single-center registry of 10,222 consecutive patients with AF presenting to the emergency department of University Hospital of Heidelberg from June 2009 until March 2020. Rates of all-cause mortality, stroke, major bleeding and myocardial infarction (MI) were related to the presence and severity of impaired presenting kidney function, as well as to assigned treatment with VKA vs. DOAC.ResultsThe risks for all-cause mortality (HR: 3.26, p<0.001), stroke (HR: 1.58, p<0.001), major bleeding (HR: 2.28, p<0.001) and MI (HR: 2.48, p<0.001) were significantly higher in patients with an eGFR<60 ml/min at admission and increased with decreasing eGFR. After adjustment for variables of CHA2DS2VASc-score, presence of eGFR <60 ml/min remained as an independent predictor for all-cause mortality, major bleeding and MI. The hazard ratio (HR) for all-cause mortality, major bleedings and MI was significantly lower in patients receiving DOAC compared to VKA.ConclusionFindings from our large real-life registry confirm the data from RCTs and extend our knowledge on the effectiveness and safety of DOACs to subjects that were underrepresented in RCTs. The impact of impaired kidney function on outcomes and treatment benefits of vitamin-K antagonists (VKA) versus direct oral anticoagulants (DOAC) in patients with atrial fibrillation (AF) has insufficiently been investigated in randomized controlled studies (RCTs). Most studies and registries are either biased due to incomplete enrolment of consecutive patients in large pharma industry sponsored registries, or due to short recruitment periods or incomplete assessment of important variables in national registries.BACKGROUNDThe impact of impaired kidney function on outcomes and treatment benefits of vitamin-K antagonists (VKA) versus direct oral anticoagulants (DOAC) in patients with atrial fibrillation (AF) has insufficiently been investigated in randomized controlled studies (RCTs). Most studies and registries are either biased due to incomplete enrolment of consecutive patients in large pharma industry sponsored registries, or due to short recruitment periods or incomplete assessment of important variables in national registries.This study uses data from the Heidelberg Registry of Atrial Fibrillation (HERA-FIB), a retrospective single-center registry of 10,222 consecutive patients with AF presenting to the emergency department of University Hospital of Heidelberg from June 2009 until March 2020. Rates of all-cause mortality, stroke, major bleeding and myocardial infarction (MI) were related to the presence and severity of impaired presenting kidney function, as well as to assigned treatment with VKA vs. DOAC.METHODSThis study uses data from the Heidelberg Registry of Atrial Fibrillation (HERA-FIB), a retrospective single-center registry of 10,222 consecutive patients with AF presenting to the emergency department of University Hospital of Heidelberg from June 2009 until March 2020. Rates of all-cause mortality, stroke, major bleeding and myocardial infarction (MI) were related to the presence and severity of impaired presenting kidney function, as well as to assigned treatment with VKA vs. DOAC.The risks for all-cause mortality (HR: 3.26, p<0.001), stroke (HR: 1.58, p<0.001), major bleeding (HR: 2.28, p<0.001) and MI (HR: 2.48, p<0.001) were significantly higher in patients with an eGFR<60 ml/min at admission and increased with decreasing eGFR. After adjustment for variables of CHA2DS2VASc-score, presence of eGFR <60 ml/min remained as an independent predictor for all-cause mortality, major bleeding and MI. The hazard ratio (HR) for all-cause mortality, major bleedings and MI was significantly lower in patients receiving DOAC compared to VKA.RESULTSThe risks for all-cause mortality (HR: 3.26, p<0.001), stroke (HR: 1.58, p<0.001), major bleeding (HR: 2.28, p<0.001) and MI (HR: 2.48, p<0.001) were significantly higher in patients with an eGFR<60 ml/min at admission and increased with decreasing eGFR. After adjustment for variables of CHA2DS2VASc-score, presence of eGFR <60 ml/min remained as an independent predictor for all-cause mortality, major bleeding and MI. The hazard ratio (HR) for all-cause mortality, major bleedings and MI was significantly lower in patients receiving DOAC compared to VKA.Findings from our large real-life registry confirm the data from RCTs and extend our knowledge on the effectiveness and safety of DOACs to subjects that were underrepresented in RCTs.CONCLUSIONFindings from our large real-life registry confirm the data from RCTs and extend our knowledge on the effectiveness and safety of DOACs to subjects that were underrepresented in RCTs. The impact of impaired kidney function on outcomes and treatment benefits of vitamin-K antagonists (VKA) versus direct oral anticoagulants (DOAC) in patients with atrial fibrillation (AF) has insufficiently been investigated in randomized controlled studies (RCTs). Most studies and registries are either biased due to incomplete enrolment of consecutive patients in large pharma industry sponsored registries, or due to short recruitment periods or incomplete assessment of important variables in national registries. This study uses data from the Heidelberg Registry of Atrial Fibrillation (HERA-FIB), a retrospective single-center registry of 10,222 consecutive patients with AF presenting to the emergency department of University Hospital of Heidelberg from June 2009 until March 2020. Rates of all-cause mortality, stroke, major bleeding and myocardial infarction (MI) were related to the presence and severity of impaired presenting kidney function, as well as to assigned treatment with VKA vs. DOAC. The risks for all-cause mortality (HR: 3.26, p<0.001), stroke (HR: 1.58, p<0.001), major bleeding (HR: 2.28, p<0.001) and MI (HR: 2.48, p<0.001) were significantly higher in patients with an eGFR<60 ml/min at admission and increased with decreasing eGFR. After adjustment for variables of CHA2DS2VASc-score, presence of eGFR <60 ml/min remained as an independent predictor for all-cause mortality, major bleeding and MI. The hazard ratio (HR) for all-cause mortality, major bleedings and MI was significantly lower in patients receiving DOAC compared to VKA. Findings from our large real-life registry confirm the data from RCTs and extend our knowledge on the effectiveness and safety of DOACs to subjects that were underrepresented in RCTs. The impact of impaired kidney function on outcomes and treatment benefits of vitamin-K antagonists (VKA) versus direct oral anticoagulants (DOAC) in patients with atrial fibrillation (AF) has insufficiently been investigated in randomized controlled studies (RCTs). Most studies and registries are either biased due to incomplete enrolment of consecutive patients in large pharma industry sponsored registries, or due to short recruitment periods or incomplete assessment of important variables in national registries. This study uses data from the Heidelberg Registry of Atrial Fibrillation (HERA-FIB), a retrospective single-center registry of 10,222 consecutive patients with AF presenting to the emergency department of University Hospital of Heidelberg from June 2009 until March 2020. Rates of all-cause mortality, stroke, major bleeding and myocardial infarction (MI) were related to the presence and severity of impaired presenting kidney function, as well as to assigned treatment with VKA vs. DOAC. The risks for all-cause mortality (HR: 3.26, p<0.001), stroke (HR: 1.58, p<0.001), major bleeding (HR: 2.28, p<0.001) and MI (HR: 2.48, p<0.001) were significantly higher in patients with an eGFR<60 ml/min at admission and increased with decreasing eGFR. After adjustment for variables of CHA.sub.2 DS.sub.2 VASc-score, presence of eGFR <60 ml/min remained as an independent predictor for all-cause mortality, major bleeding and MI. The hazard ratio (HR) for all-cause mortality, major bleedings and MI was significantly lower in patients receiving DOAC compared to VKA. Background The impact of impaired kidney function on outcomes and treatment benefits of vitamin-K antagonists (VKA) versus direct oral anticoagulants (DOAC) in patients with atrial fibrillation (AF) has insufficiently been investigated in randomized controlled studies (RCTs). Most studies and registries are either biased due to incomplete enrolment of consecutive patients in large pharma industry sponsored registries, or due to short recruitment periods or incomplete assessment of important variables in national registries. Methods This study uses data from the Heidelberg Registry of Atrial Fibrillation (HERA-FIB), a retrospective single-center registry of 10,222 consecutive patients with AF presenting to the emergency department of University Hospital of Heidelberg from June 2009 until March 2020. Rates of all-cause mortality, stroke, major bleeding and myocardial infarction (MI) were related to the presence and severity of impaired presenting kidney function, as well as to assigned treatment with VKA vs. DOAC. Results The risks for all-cause mortality (HR: 3.26, p<0.001), stroke (HR: 1.58, p<0.001), major bleeding (HR: 2.28, p<0.001) and MI (HR: 2.48, p<0.001) were significantly higher in patients with an eGFR<60 ml/min at admission and increased with decreasing eGFR. After adjustment for variables of CHA 2 DS 2 VASc-score, presence of eGFR <60 ml/min remained as an independent predictor for all-cause mortality, major bleeding and MI. The hazard ratio (HR) for all-cause mortality, major bleedings and MI was significantly lower in patients receiving DOAC compared to VKA. Conclusion Findings from our large real-life registry confirm the data from RCTs and extend our knowledge on the effectiveness and safety of DOACs to subjects that were underrepresented in RCTs. Background The impact of impaired kidney function on outcomes and treatment benefits of vitamin-K antagonists (VKA) versus direct oral anticoagulants (DOAC) in patients with atrial fibrillation (AF) has insufficiently been investigated in randomized controlled studies (RCTs). Most studies and registries are either biased due to incomplete enrolment of consecutive patients in large pharma industry sponsored registries, or due to short recruitment periods or incomplete assessment of important variables in national registries. Methods This study uses data from the Heidelberg Registry of Atrial Fibrillation (HERA-FIB), a retrospective single-center registry of 10,222 consecutive patients with AF presenting to the emergency department of University Hospital of Heidelberg from June 2009 until March 2020. Rates of all-cause mortality, stroke, major bleeding and myocardial infarction (MI) were related to the presence and severity of impaired presenting kidney function, as well as to assigned treatment with VKA vs. DOAC. Results The risks for all-cause mortality (HR: 3.26, p<0.001), stroke (HR: 1.58, p<0.001), major bleeding (HR: 2.28, p<0.001) and MI (HR: 2.48, p<0.001) were significantly higher in patients with an eGFR<60 ml/min at admission and increased with decreasing eGFR. After adjustment for variables of CHA.sub.2 DS.sub.2 VASc-score, presence of eGFR <60 ml/min remained as an independent predictor for all-cause mortality, major bleeding and MI. The hazard ratio (HR) for all-cause mortality, major bleedings and MI was significantly lower in patients receiving DOAC compared to VKA. Conclusion Findings from our large real-life registry confirm the data from RCTs and extend our knowledge on the effectiveness and safety of DOACs to subjects that were underrepresented in RCTs. |
| Audience | Academic |
| Author | Milles, Barbara Ruth Yildirim, Mustafa Katus, Hugo Salbach, Christian Giannitsis, Evangelos Biener, Moritz Mueller-Hennessen, Matthias Hund, Hauke Frey, Norbert |
| AuthorAffiliation | Department of Internal Medicine III, Cardiology, University Hospital of Heidelberg, Heidelberg, Germany Sapienza University of Rome: Universita degli Studi di Roma La Sapienza, ITALY |
| AuthorAffiliation_xml | – name: Sapienza University of Rome: Universita degli Studi di Roma La Sapienza, ITALY – name: Department of Internal Medicine III, Cardiology, University Hospital of Heidelberg, Heidelberg, Germany |
| Author_xml | – sequence: 1 givenname: Christian orcidid: 0000-0002-1799-545X surname: Salbach fullname: Salbach, Christian – sequence: 2 givenname: Barbara Ruth orcidid: 0009-0004-4602-5489 surname: Milles fullname: Milles, Barbara Ruth – sequence: 3 givenname: Hauke surname: Hund fullname: Hund, Hauke – sequence: 4 givenname: Moritz orcidid: 0000-0001-6763-6538 surname: Biener fullname: Biener, Moritz – sequence: 5 givenname: Matthias surname: Mueller-Hennessen fullname: Mueller-Hennessen, Matthias – sequence: 6 givenname: Norbert surname: Frey fullname: Frey, Norbert – sequence: 7 givenname: Hugo surname: Katus fullname: Katus, Hugo – sequence: 8 givenname: Evangelos surname: Giannitsis fullname: Giannitsis, Evangelos – sequence: 9 givenname: Mustafa surname: Yildirim fullname: Yildirim, Mustafa |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/39312541$$D View this record in MEDLINE/PubMed |
| BookMark | eNqNk9tu1DAQhiNURA_wBggsISG42MWOEye5QlVVoFKlSpxurVnH3nVJ7MV2KPs2PCqT3bTqol6gRIplf_8_mRnPcXbgvNNZ9pzROeMVe3fth-Cgm69xe045ozWvH2VHrOH5TOSUH9xbH2bHMV5TWvJaiCfZIW84y8uCHWV_zo3RKhFviO3XYINuyQ_bOr0hZnAqWe_I-A5J-V5HAq4lKWhIvXaJ6K04jmofoMPTZJWH5dDhigS9tKPGOrKGZFEQyY1NKwIpWKSNXQTbdbANghCgArrZjQ9duxXHFDZPs8cGuqifTd-T7NuH869nn2aXVx8vzk4vZ6qsRJpxpitTFJpXUKkKVKEEKCUoU3oBCxBVA7ysyjxnudGtok1Tc2CKq0VbcSUafpK93PmuOx_lVNwox7qWVd7kAon3EzEsevTAfDBnuQ62h7CRHqzcP3F2JZf-l2SswE6UFB3eTA7B_xx0TLK3UWksgdN-2AWrBG9Ejeirf9CHf2miltBpaZ3xGFiNpvK0pg1aYc5IzR-g8Gl1j-1y2ljc3xO83RMgk_TvtIQhRnnx5fP_s1ff99nX99gVNjutou-G8QLEffDF_VLf1fj23iJQ7AAVfIxBmzuEUTmOx2255DgechoP_hekzgWv |
| Cites_doi | 10.1378/chest.10-0134 10.1186/s12959-019-0211-y 10.1056/NEJMoa1107039 10.1056/NEJMoa1009638 10.1016/j.jacc.2014.10.052 10.1016/S0140-6736(19)32977-0 10.1016/j.jacc.2014.09.051 10.1016/S0140-6736(13)62343-0 10.1161/CIRCULATIONAHA.111.020982 10.1016/j.lanepe.2022.100438 10.1093/ehjqcco/qcab069 10.1016/j.amjmed.2016.09.012 10.1056/NEJMoa1310907 10.1093/eurheartj/ehaa612 10.1161/CIRCULATIONAHA.116.022802 10.1378/chest.09-1584 10.1016/j.ahj.2010.03.027 10.1161/JAHA.118.010510 10.1056/NEJMoa1105594 10.1007/s11739-021-02799-5 10.1161/CIR.0000000000000617 10.1016/S0140-6736(16)32064-5 10.1093/eurheartj/ehv466 10.1161/JAHA.123.033396 10.2217/fca-2020-0014 10.1111/j.1538-7836.2005.01204.x 10.1136/bmj.d124 10.1016/j.amjcard.2021.05.004 10.1093/ehjcvp/pvac042 10.1161/CIRCULATIONAHA.112.107128 10.1161/CIRCULATIONAHA.116.022361 10.1136/bmj.h5876 10.3389/fcvm.2022.1042763 10.1161/JAHA.118.008987 10.1056/NEJMoa0905561 10.1053/j.ajkd.2019.01.001 |
| ContentType | Journal Article |
| Copyright | Copyright: © 2024 Salbach et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. COPYRIGHT 2024 Public Library of Science 2024 Salbach et al. This is an open access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. 2024 Salbach et al 2024 Salbach et al 2024 Salbach et al. This is an open access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| Copyright_xml | – notice: Copyright: © 2024 Salbach et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. – notice: COPYRIGHT 2024 Public Library of Science – notice: 2024 Salbach et al. This is an open access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: 2024 Salbach et al 2024 Salbach et al – notice: 2024 Salbach et al. This is an open access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| DBID | AAYXX CITATION NPM IOV ISR 3V. 7QG 7QL 7QO 7RV 7SN 7SS 7T5 7TG 7TM 7U9 7X2 7X7 7XB 88E 8AO 8C1 8FD 8FE 8FG 8FH 8FI 8FJ 8FK ABJCF ABUWG AEUYN AFKRA ARAPS ATCPS AZQEC BBNVY BENPR BGLVJ BHPHI C1K CCPQU D1I DWQXO FR3 FYUFA GHDGH GNUQQ H94 HCIFZ K9. KB. KB0 KL. L6V LK8 M0K M0S M1P M7N M7P M7S NAPCQ P5Z P62 P64 PATMY PDBOC PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQGLB PQQKQ PQUKI PRINS PTHSS PYCSY RC3 7X8 5PM |
| DOI | 10.1371/journal.pone.0310838 |
| DatabaseName | CrossRef PubMed Opposing Viewpoints in Context Gale In Context: Science ProQuest Central (Corporate) Animal Behavior Abstracts Bacteriology Abstracts (Microbiology B) Biotechnology Research Abstracts Nursing & Allied Health Database Ecology Abstracts Entomology Abstracts (Full archive) Immunology Abstracts Meteorological & Geoastrophysical Abstracts Nucleic Acids Abstracts Virology and AIDS Abstracts Agricultural Science Collection Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) ProQuest Pharma Collection Public Health Database Technology Research Database ProQuest SciTech Collection ProQuest Technology Collection ProQuest Natural Science Collection Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) Materials Science & Engineering Collection ProQuest Central (Alumni) ProQuest One Sustainability ProQuest Central UK/Ireland Advanced Technologies & Aerospace Collection Agricultural & Environmental Science Collection ProQuest Central Essentials - QC Biological Science Collection ProQuest Central Technology Collection Natural Science Collection Environmental Sciences and Pollution Management ProQuest One ProQuest Materials Science Collection ProQuest Central Korea Engineering Research Database Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student AIDS and Cancer Research Abstracts SciTech Premium Collection ProQuest Health & Medical Complete (Alumni) Materials Science Database Nursing & Allied Health Database (Alumni Edition) Meteorological & Geoastrophysical Abstracts - Academic ProQuest Engineering Collection Biological Sciences Agriculture Science Database ProQuest Health & Medical Collection Medical Database Algology Mycology and Protozoology Abstracts (Microbiology C) Biological Science Database Engineering Database Nursing & Allied Health Premium Advanced Technologies & Aerospace Database ProQuest Advanced Technologies & Aerospace Collection Biotechnology and BioEngineering Abstracts Environmental Science Database Materials Science Collection ProQuest Central Premium ProQuest One Academic (New) Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Applied & Life Sciences ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China Engineering Collection Environmental Science Collection Genetics Abstracts MEDLINE - Academic PubMed Central (Full Participant titles) |
| DatabaseTitle | CrossRef PubMed Agricultural Science Database Publicly Available Content Database ProQuest Central Student ProQuest Advanced Technologies & Aerospace Collection ProQuest Central Essentials Nucleic Acids Abstracts SciTech Premium Collection ProQuest Central China Environmental Sciences and Pollution Management ProQuest One Applied & Life Sciences ProQuest One Sustainability Health Research Premium Collection Meteorological & Geoastrophysical Abstracts Natural Science Collection Health & Medical Research Collection Biological Science Collection ProQuest Central (New) ProQuest Medical Library (Alumni) Engineering Collection Advanced Technologies & Aerospace Collection Engineering Database Virology and AIDS Abstracts ProQuest Biological Science Collection ProQuest One Academic Eastern Edition Agricultural Science Collection ProQuest Hospital Collection ProQuest Technology Collection Health Research Premium Collection (Alumni) Biological Science Database Ecology Abstracts ProQuest Hospital Collection (Alumni) Biotechnology and BioEngineering Abstracts Environmental Science Collection Entomology Abstracts Nursing & Allied Health Premium ProQuest Health & Medical Complete ProQuest One Academic UKI Edition Environmental Science Database ProQuest Nursing & Allied Health Source (Alumni) Engineering Research Database ProQuest One Academic Meteorological & Geoastrophysical Abstracts - Academic ProQuest One Academic (New) Technology Collection Technology Research Database ProQuest One Academic Middle East (New) Materials Science Collection ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Natural Science Collection ProQuest Pharma Collection ProQuest Central ProQuest Health & Medical Research Collection Genetics Abstracts ProQuest Engineering Collection Biotechnology Research Abstracts Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Bacteriology Abstracts (Microbiology B) Algology Mycology and Protozoology Abstracts (Microbiology C) Agricultural & Environmental Science Collection AIDS and Cancer Research Abstracts Materials Science Database ProQuest Materials Science Collection ProQuest Public Health ProQuest Nursing & Allied Health Source ProQuest SciTech Collection Advanced Technologies & Aerospace Database ProQuest Medical Library Animal Behavior Abstracts Materials Science & Engineering Collection Immunology Abstracts ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | Agricultural Science Database MEDLINE - Academic PubMed |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 8FG name: ProQuest Technology Collection url: https://search.proquest.com/technologycollection1 sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Sciences (General) |
| DocumentTitleAlternate | Effect of impaired kidney function on outcomes in atrial fibrillation |
| EISSN | 1932-6203 |
| ExternalDocumentID | 3108572926 PMC11419350 A809639575 39312541 10_1371_journal_pone_0310838 |
| Genre | Journal Article |
| GeographicLocations | Germany |
| GeographicLocations_xml | – name: Germany |
| GrantInformation_xml | – fundername: ; |
| GroupedDBID | --- 123 29O 2WC 53G 5VS 7RV 7X2 7X7 7XC 88E 8AO 8C1 8CJ 8FE 8FG 8FH 8FI 8FJ A8Z AAFWJ AAUCC AAWOE AAYXX ABDBF ABIVO ABJCF ABUWG ACGFO ACIHN ACIWK ACPRK ACUHS ADBBV AEAQA AENEX AEUYN AFKRA AFPKN AFRAH AHMBA ALIPV ALMA_UNASSIGNED_HOLDINGS AOIJS APEBS ARAPS ATCPS BAWUL BBNVY BCNDV BENPR BGLVJ BHPHI BKEYQ BPHCQ BVXVI BWKFM CCPQU CITATION CS3 D1I D1J D1K DIK DU5 E3Z EAP EAS EBD EMOBN ESX EX3 F5P FPL FYUFA GROUPED_DOAJ GX1 HCIFZ HH5 HMCUK HYE IAO IEA IGS IHR IHW INH INR IOV IPY ISE ISR ITC K6- KB. KQ8 L6V LK5 LK8 M0K M1P M48 M7P M7R M7S M~E NAPCQ O5R O5S OK1 OVT P2P P62 PATMY PDBOC PHGZM PHGZT PIMPY PQQKQ PROAC PSQYO PTHSS PV9 PYCSY RNS RPM RZL SV3 TR2 UKHRP WOQ WOW ~02 ~KM 3V. ADRAZ BBORY IPNFZ NPM RIG PMFND 7QG 7QL 7QO 7SN 7SS 7T5 7TG 7TM 7U9 7XB 8FD 8FK AZQEC C1K DWQXO FR3 GNUQQ H94 K9. KL. M7N P64 PJZUB PKEHL PPXIY PQEST PQGLB PQUKI PRINS RC3 7X8 ESTFP PUEGO 5PM |
| ID | FETCH-LOGICAL-c576t-31e7f44e37a7c7ac4c6acc601cebaba679a35752212fedc09983a1c3cbd73c693 |
| IEDL.DBID | M48 |
| ISSN | 1932-6203 |
| IngestDate | Wed Dec 25 02:22:10 EST 2024 Thu Aug 21 18:31:02 EDT 2025 Fri Sep 05 11:04:50 EDT 2025 Fri Jul 25 10:37:30 EDT 2025 Tue Jun 17 22:03:54 EDT 2025 Tue Jun 10 20:58:06 EDT 2025 Fri Jun 27 05:25:10 EDT 2025 Fri Jun 27 05:25:31 EDT 2025 Thu May 22 21:26:38 EDT 2025 Wed Feb 19 02:07:33 EST 2025 Tue Jul 01 03:45:11 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 9 |
| Language | English |
| License | Copyright: © 2024 Salbach et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Creative Commons Attribution License |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c576t-31e7f44e37a7c7ac4c6acc601cebaba679a35752212fedc09983a1c3cbd73c693 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 Competing Interests: MMH received research funding from BRAHMS, Thermo Fisher Scientific and Roche Diagnostics. MB received research support from AstraZeneca outside the submitted work. EG received honoraria for lectures from Roche Diagnostics, AstraZeneca, Bayer, Daiichi-Sankyo, Lilly Eli Deutschland. He serves as a consultant for Roche Diagnostics, BRAHMS Thermo Fisher Scientific, Boehringer Ingelheim and has received research funding from BRAHMS Thermo Fisher Scientific, Roche Diagnostics, Bayer Vital and Daiichi Sankyo. NF has received speaker honoraria from Daiichi Sankyo, Astra Zeneca, Boehringer Ingelheim and Bayer Vital. He serves as a consultant for ZOLL CMS. BRM, received research funding from Daiichi Sankyo. There are no disclosures for MY, HH and CS. We also state that the competing interests’ statement does not alter our adherence to PLOS ONE policies on sharing data and materials. All co-authors have approved the revised version of the manuscript. |
| ORCID | 0009-0004-4602-5489 0000-0001-6763-6538 0000-0002-1799-545X |
| OpenAccessLink | http://journals.scholarsportal.info/openUrl.xqy?doi=10.1371/journal.pone.0310838 |
| PMID | 39312541 |
| PQID | 3108572926 |
| PQPubID | 1436336 |
| PageCount | e0310838 |
| ParticipantIDs | plos_journals_3108572926 pubmedcentral_primary_oai_pubmedcentral_nih_gov_11419350 proquest_miscellaneous_3108763968 proquest_journals_3108572926 gale_infotracmisc_A809639575 gale_infotracacademiconefile_A809639575 gale_incontextgauss_ISR_A809639575 gale_incontextgauss_IOV_A809639575 gale_healthsolutions_A809639575 pubmed_primary_39312541 crossref_primary_10_1371_journal_pone_0310838 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2024-09-23 |
| PublicationDateYYYYMMDD | 2024-09-23 |
| PublicationDate_xml | – month: 09 year: 2024 text: 2024-09-23 day: 23 |
| PublicationDecade | 2020 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States – name: San Francisco – name: San Francisco, CA USA |
| PublicationTitle | PloS one |
| PublicationTitleAlternate | PLoS One |
| PublicationYear | 2024 |
| Publisher | Public Library of Science |
| Publisher_xml | – name: Public Library of Science |
| References | EC O’Brien (pone.0310838.ref014) 2015; 36 RP Giugliano (pone.0310838.ref038) 2013; 369 R Saran (pone.0310838.ref023) 2019; 73 KAA Fox (pone.0310838.ref028) 2017; 3 JP Bassand (pone.0310838.ref032) 2021; 17 R Pisters (pone.0310838.ref013) 2010; 138 GR Marzouka (pone.0310838.ref037) 2021; 155 EK Laugesen (pone.0310838.ref002) 2019; 17 J Sundstrom (pone.0310838.ref022) 2022; 20 S Goto (pone.0310838.ref008) 2019; 8 A Abugroun (pone.0310838.ref036) 2020; 28 EZ Soliman (pone.0310838.ref021) 2010; 159 K Thygesen (pone.0310838.ref015) 2018; 138 A Alonso (pone.0310838.ref001) 2011; 123 JP Piccini (pone.0310838.ref006) 2013; 127 S Schulman (pone.0310838.ref011) 2005; 3 SJ Connolly (pone.0310838.ref020) 2009; 361 P Kirchhof (pone.0310838.ref034) 2022; 9 M Proietti (pone.0310838.ref026) 2022; 8 JB Olesen (pone.0310838.ref005) 2012; 367 CL Fanola (pone.0310838.ref018) 2018; 7 M Mazurek (pone.0310838.ref027) 2017; 130 L Staerk (pone.0310838.ref029) 2015; 351 GY Lip (pone.0310838.ref012) 2010; 137 CB Granger (pone.0310838.ref017) 2011; 365 X Liu (pone.0310838.ref025) 2022; 9 AJ Camm (pone.0310838.ref033) 2016; 37 C Salbach (pone.0310838.ref009) 2024 MR Patel (pone.0310838.ref019) 2011; 365 CT Ruff (pone.0310838.ref016) 2014; 383 EA Bohula (pone.0310838.ref039) 2016; 134 JB Olesen (pone.0310838.ref030) 2011; 342 G Hindricks (pone.0310838.ref007) 2021; 42 AC Webster (pone.0310838.ref010) 2017; 389 L Friberg (pone.0310838.ref031) 2015; 65 C Goudis (pone.0310838.ref035) 2021; 16 AN Bonde (pone.0310838.ref004) 2014; 64 P Cockwell (pone.0310838.ref003) 2020; 395 J Oldgren (pone.0310838.ref024) 2016; 134 |
| References_xml | – volume: 138 start-page: 1093 issue: 5 year: 2010 ident: pone.0310838.ref013 article-title: A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. publication-title: Chest doi: 10.1378/chest.10-0134 – volume: 3 start-page: 114 issue: 2 year: 2017 ident: pone.0310838.ref028 article-title: Evolving quality standards for large-scale registries: the GARFIELD-AF experience publication-title: Eur Heart J Qual Care Clin Outcomes – volume: 17 start-page: 21 year: 2019 ident: pone.0310838.ref002 article-title: Non-vitamin K antagonist oral anticoagulants vs. vitamin-K antagonists in patients with atrial fibrillation and chronic kidney disease: a nationwide cohort study. publication-title: Thromb J. doi: 10.1186/s12959-019-0211-y – volume: 365 start-page: 981 issue: 11 year: 2011 ident: pone.0310838.ref017 article-title: Apixaban versus warfarin in patients with atrial fibrillation publication-title: N Engl J Med doi: 10.1056/NEJMoa1107039 – volume: 365 start-page: 883 issue: 10 year: 2011 ident: pone.0310838.ref019 article-title: Rivaroxaban versus warfarin in nonvalvular atrial fibrillation publication-title: N Engl J Med doi: 10.1056/NEJMoa1009638 – volume: 65 start-page: 225 issue: 3 year: 2015 ident: pone.0310838.ref031 article-title: Benefit of anticoagulation unlikely in patients with atrial fibrillation and a CHA2DS2-VASc score of 1 publication-title: J Am Coll Cardiol doi: 10.1016/j.jacc.2014.10.052 – volume: 395 start-page: 662 issue: 10225 year: 2020 ident: pone.0310838.ref003 article-title: The global burden of chronic kidney disease publication-title: Lancet doi: 10.1016/S0140-6736(19)32977-0 – volume: 64 start-page: 2471 issue: 23 year: 2014 ident: pone.0310838.ref004 article-title: Net clinical benefit of antithrombotic therapy in patients with atrial fibrillation and chronic kidney disease: a nationwide observational cohort study publication-title: J Am Coll Cardiol doi: 10.1016/j.jacc.2014.09.051 – volume: 36 start-page: 3258 issue: 46 year: 2015 ident: pone.0310838.ref014 article-title: The ORBIT bleeding score: a simple bedside score to assess bleeding risk in atrial fibrillation publication-title: Eur Heart J – volume: 383 start-page: 955 issue: 9921 year: 2014 ident: pone.0310838.ref016 article-title: Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials publication-title: Lancet doi: 10.1016/S0140-6736(13)62343-0 – volume: 123 start-page: 2946 issue: 25 year: 2011 ident: pone.0310838.ref001 article-title: Chronic kidney disease is associated with the incidence of atrial fibrillation: the Atherosclerosis Risk in Communities (ARIC) study. publication-title: Circulation doi: 10.1161/CIRCULATIONAHA.111.020982 – volume: 20 start-page: 100438 year: 2022 ident: pone.0310838.ref022 article-title: Prevalence, outcomes, and cost of chronic kidney disease in a contemporary population of 2.4 million patients from 11 countries: The CaReMe CKD study publication-title: Lancet Reg Health Eur doi: 10.1016/j.lanepe.2022.100438 – volume: 8 start-page: 778 issue: 7 year: 2022 ident: pone.0310838.ref026 article-title: Comparison of HAS-BLED and ORBIT bleeding risk scores in atrial fibrillation patients treated with non-vitamin K antagonist oral anticoagulants: a report from the ESC-EHRA EORP-AF General Long-Term Registry publication-title: Eur Heart J Qual Care Clin Outcomes doi: 10.1093/ehjqcco/qcab069 – volume: 130 start-page: 135 issue: 2 year: 2017 ident: pone.0310838.ref027 article-title: Registries in Atrial Fibrillation: From Trials to Real-Life Clinical Practice publication-title: Am J Med doi: 10.1016/j.amjmed.2016.09.012 – volume: 369 start-page: 2093 issue: 22 year: 2013 ident: pone.0310838.ref038 article-title: Edoxaban versus warfarin in patients with atrial fibrillation publication-title: N Engl J Med doi: 10.1056/NEJMoa1310907 – volume: 42 start-page: 373 issue: 5 year: 2021 ident: pone.0310838.ref007 article-title: 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. publication-title: Eur Heart J doi: 10.1093/eurheartj/ehaa612 – volume: 134 start-page: 1697 issue: 22 year: 2016 ident: pone.0310838.ref024 article-title: Performance and Validation of a Novel Biomarker-Based Stroke Risk Score for Atrial Fibrillation publication-title: Circulation doi: 10.1161/CIRCULATIONAHA.116.022802 – volume: 137 start-page: 263 issue: 2 year: 2010 ident: pone.0310838.ref012 article-title: Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation publication-title: Chest doi: 10.1378/chest.09-1584 – volume: 159 start-page: 1102 issue: 6 year: 2010 ident: pone.0310838.ref021 article-title: Chronic kidney disease and prevalent atrial fibrillation: the Chronic Renal Insufficiency Cohort (CRIC). publication-title: Am Heart J doi: 10.1016/j.ahj.2010.03.027 – volume: 8 start-page: e010510 issue: 3 year: 2019 ident: pone.0310838.ref008 article-title: Management and 1-Year Outcomes of Patients With Newly Diagnosed Atrial Fibrillation and Chronic Kidney Disease: Results From the Prospective GARFIELD—AF Registry. publication-title: J Am Heart Assoc doi: 10.1161/JAHA.118.010510 – volume: 367 start-page: 625 issue: 7 year: 2012 ident: pone.0310838.ref005 article-title: Stroke and bleeding in atrial fibrillation with chronic kidney disease publication-title: N Engl J Med doi: 10.1056/NEJMoa1105594 – volume: 16 start-page: 1737 issue: 7 year: 2021 ident: pone.0310838.ref035 article-title: Does CHA2DS2-VASc score predict mortality in chronic kidney disease? publication-title: Intern Emerg Med doi: 10.1007/s11739-021-02799-5 – volume: 138 start-page: e618 issue: 20 year: 2018 ident: pone.0310838.ref015 article-title: Fourth Universal Definition of Myocardial Infarction (2018). publication-title: Circulation doi: 10.1161/CIR.0000000000000617 – volume: 389 start-page: 1238 issue: 10075 year: 2017 ident: pone.0310838.ref010 article-title: Chronic Kidney Disease. publication-title: Lancet doi: 10.1016/S0140-6736(16)32064-5 – volume: 37 start-page: 1145 issue: 14 year: 2016 ident: pone.0310838.ref033 article-title: XANTUS: a real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation publication-title: Eur Heart J doi: 10.1093/eurheartj/ehv466 – volume: 28 start-page: 100532 year: 2020 ident: pone.0310838.ref036 article-title: Modified CHA(2)DS(2)-VASc score predicts in-hospital mortality and procedural complications in acute coronary syndrome treated with percutaneous coronary intervention. publication-title: Int J Cardiol Heart Vasc – start-page: e033396 year: 2024 ident: pone.0310838.ref009 article-title: Design, Rationale and Initial Findings From HERA-FIB on 10 222 Patients With Atrial Fibrillation Presenting to an Emergency Department Over An 11-Year Period. publication-title: J Am Heart Assoc doi: 10.1161/JAHA.123.033396 – volume: 17 start-page: 19 issue: 1 year: 2021 ident: pone.0310838.ref032 article-title: GARFIELD-AF: a worldwide prospective registry of patients with atrial fibrillation at risk of stroke publication-title: Future Cardiol doi: 10.2217/fca-2020-0014 – volume: 3 start-page: 692 issue: 4 year: 2005 ident: pone.0310838.ref011 article-title: Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients publication-title: J Thromb Haemost doi: 10.1111/j.1538-7836.2005.01204.x – volume: 342 start-page: d124 year: 2011 ident: pone.0310838.ref030 article-title: Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: nationwide cohort study publication-title: BMJ doi: 10.1136/bmj.d124 – volume: 155 start-page: 72 year: 2021 ident: pone.0310838.ref037 article-title: The CHA(2)DS(2)-VASc Score for Risk Stratification of Stroke in Heart Failure With-vs-Without Atrial Fibrillation. publication-title: Am J Cardiol doi: 10.1016/j.amjcard.2021.05.004 – volume: 9 start-page: 47 issue: 1 year: 2022 ident: pone.0310838.ref034 article-title: Edoxaban for stroke prevention in atrial fibrillation and age-adjusted predictors of clinical outcomes in routine clinical care publication-title: Eur Heart J Cardiovasc Pharmacother doi: 10.1093/ehjcvp/pvac042 – volume: 127 start-page: 224 issue: 2 year: 2013 ident: pone.0310838.ref006 article-title: Renal dysfunction as a predictor of stroke and systemic embolism in patients with nonvalvular atrial fibrillation: validation of the R(2)CHADS(2) index in the ROCKET AF (Rivaroxaban Once-daily, oral, direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (AnTicoagulation and Risk factors In Atrial fibrillation) study cohorts. publication-title: Circulation doi: 10.1161/CIRCULATIONAHA.112.107128 – volume: 134 start-page: 24 issue: 1 year: 2016 ident: pone.0310838.ref039 article-title: Impact of Renal Function on Outcomes With Edoxaban in the ENGAGE AF-TIMI 48 Trial. publication-title: Circulation doi: 10.1161/CIRCULATIONAHA.116.022361 – volume: 351 start-page: h5876 year: 2015 ident: pone.0310838.ref029 article-title: Stroke and recurrent haemorrhage associated with antithrombotic treatment after gastrointestinal bleeding in patients with atrial fibrillation: nationwide cohort study publication-title: BMJ doi: 10.1136/bmj.h5876 – volume: 9 start-page: 1042763 year: 2022 ident: pone.0310838.ref025 article-title: HAS-BLED vs. ORBIT scores in anticoagulated patients with atrial fibrillation: A systematic review and meta-analysis. publication-title: Front Cardiovasc Med. doi: 10.3389/fcvm.2022.1042763 – volume: 7 start-page: e008987 issue: 16 year: 2018 ident: pone.0310838.ref018 article-title: Efficacy and Safety of Edoxaban in Patients With Active Malignancy and Atrial Fibrillation: Analysis of the ENGAGE AF—TIMI 48 Trial. publication-title: J Am Heart Assoc doi: 10.1161/JAHA.118.008987 – volume: 361 start-page: 1139 issue: 12 year: 2009 ident: pone.0310838.ref020 article-title: Dabigatran versus warfarin in patients with atrial fibrillation publication-title: N Engl J Med doi: 10.1056/NEJMoa0905561 – volume: 73 start-page: A7 issue: 3 Suppl 1 year: 2019 ident: pone.0310838.ref023 article-title: US Renal Data System 2018 Annual Data Report: Epidemiology of Kidney Disease in the United States publication-title: Am J Kidney Dis doi: 10.1053/j.ajkd.2019.01.001 |
| SSID | ssj0053866 |
| Score | 2.4578881 |
| Snippet | The impact of impaired kidney function on outcomes and treatment benefits of vitamin-K antagonists (VKA) versus direct oral anticoagulants (DOAC) in patients... Background The impact of impaired kidney function on outcomes and treatment benefits of vitamin-K antagonists (VKA) versus direct oral anticoagulants (DOAC) in... BackgroundThe impact of impaired kidney function on outcomes and treatment benefits of vitamin-K antagonists (VKA) versus direct oral anticoagulants (DOAC) in... Background The impact of impaired kidney function on outcomes and treatment benefits of vitamin-K antagonists (VKA) versus direct oral anticoagulants (DOAC) in... |
| SourceID | plos pubmedcentral proquest gale pubmed crossref |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database |
| StartPage | e0310838 |
| SubjectTerms | Age Analysis Antagonists Anticoagulants Anticoagulants (Medicine) Atrial fibrillation Biology and Life Sciences Bleeding Cardiac arrhythmia Care and treatment Cerebral infarction Clopidogrel Data collection Diabetes Diagnosis Dosage and administration Emergency medical care Emergency medical services Emergency service Epidermal growth factor receptors Fibrillation Germany Heart attacks Hospitals Hypertension Ischemia Kidney diseases Kidney function tests Kidneys Medicine and Health Sciences Mortality Myocardial infarction Patient outcomes Patients Pharmaceuticals Research and Analysis Methods Stroke |
| SummonAdditionalLinks | – databaseName: ProQuest Technology Collection dbid: 8FG link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3db9MwELegvPCC2PhYYYBBSMBDtiVO7eQJTdPKQAIkYGhvkWM7o6JyCmkf-G_4U_ld4oRlmhBS1YfeXZvenX139n0w9jymUZgIlCO4BiJKHQKU3CV5lJdwnjOhS9W2zH__QZ6cpu_OZmfhwK0JaZX9nthu1LY2dEa-LyhNHp5gIl-vfkQ0NYpuV8MIjevsRgxLQ3qezd_0OzHWspShXE6oeD9IZ29Ve7dHLTEzqkq5YI7CpjxZLevmKo_zcuLkBUs0v81uBReSH3Yy32LXnN9mW2GRNvxl6CT96g773fUm5nXFqRoSu5vl3xfWu1-c7BnJhNNrswYPQKq95UPmOQ-pHkRNZfyA4gdrTbPrAaWJDkSz8Dz0Zm04Hepy3Q4C4RXVEiy7TDtC0qDQy6jt0NoS05S5u-x0fvzl6CQKIxkig8BkjR3bqSpNnVBaGaVNaqQ2BkGdcaUutVS5FnAAExjECmyC-wl5x0aY0iphZC7usYkH-3cYhyeET8g4GryVtrQil4m1sTmoXJZmUxb1kilWXeeNor1-U4hYOk4XJMkiSHLKnpD4iq5-dFi4xWGGKI1uI2dT9qzFoLYXnvJqzvWmaYq3H7_-B9LnTyOkFwGpqqEIRodaBjwOtdMaYe6OMLF4zQi8Q8rW_6Gm-KvmoOwV8Grw0wFMX0q5ct7Vmw4HViOXYMn9Tl8HBoLn8GjTeMqykSYPCNRtfAzxi29t13EEznD2ZwcP_v1cD9nNBH4fpdQkYpdN1j837hH8tnX5uF2cfwAHakZ_ priority: 102 providerName: ProQuest |
| Title | Effect of impaired kidney function on outcomes and treatment effects of oral anticoagulant regimes in patients with atrial fibrillation in a real-world registry |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/39312541 https://www.proquest.com/docview/3108572926 https://www.proquest.com/docview/3108763968 https://pubmed.ncbi.nlm.nih.gov/PMC11419350 http://dx.doi.org/10.1371/journal.pone.0310838 |
| Volume | 19 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3db9MwELe27oUXtPG1wigGIQEPqZY4jZMHhMa0MpA20KCob5HjOKNalZSlldh_w5_K7xw3IqiTkCo_9O7a5HyXu4vvg7GXPo3CRKDswTUQXmgQoCQmSLwkg_McC5VJ2zL_7Dw6nYSfpqPpFlvPbHUMrDeGdjRPanI9H_76efMOCv_WTm2Q_ppouKhKM6RWl7GIt9kObFNE4dhZ2J4rQLujyBXQ3UbZMVDuMd1bzKt6kw_6byrlX7ZpvMvuOqeSHzVSsMe2THmP7Tm1rflr11v6zX32u-lWzKuCU30knnc5v5rlpbnhZOFolzh9VktIIkhVmfM2F5275A-ipsJ-QPGHlaJp9oDSjAeimZXcdWutOb3m5cqOBuEFVRfMm9w7QlKgUHPP9my1xDR37gGbjE--HZ96bkiDpxGqLPEMN7IIQyOkkloqHepIaY0wT5tMZSqSiRJwCQOYyAJsgkMKCfC10FkuhY4S8ZD1SrB_n3H4RviGzKXGkuVZLpIoyHNfHxYmDuM-89Y7ky6aXhypPZCTiGEaTqe0k6nbyT57RtuXNhWlrSqnRzHiNjqfHPXZC4tBjTBKyrS5VKu6Tj9-_v4fSF8vOkivHFJRQRC0ctUNuBxqsNXBPOhgQp11B7xPwra-oTqlexkhBAoiUK4FcDP4eQumH6XsudJUqwYHdiSJwJJHjby2DATP4eOGfp_FHUluEaj_eBdSzn7YPuQIpeH-jw4f337JT9idAF4gJdgE4oD1ltcr8xRe3DIbsG05lVjjY5_W8YcB23l_cv7lYmDfiwys4v4By0xPuQ |
| linkProvider | Scholars Portal |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1bb9MwFLam8gAviHFb2WAGgYCHbMulcfKA0ARMLbsgwYb6FhzbGdWqpJBGaP-GX8Bv5DuJExY0IV4mVVVVH6eufXwu9jnfYeypS6Uw4Sg7MA18JzBwUGLjxU6cwniOfJmKGjL_8CgcnwTvp6PpCvvV5sJQWGUrE2tBrQtFZ-TbPoXJwxL0wteLbw5VjaLb1baERsMW--b8B1y28tXkLdb3meftvTt-M3ZsVQFHwbZeQugYkQWB8YUUSkgVqFAqBb9EmVSmMhSx9GHDeJDpmdEKFhSG7CpfpVr4KiTwJYj8awGdjGP_iGnn4EF2hKFNz_OFu225YWtR5GaLIDgjyoK5oP6sEhgs5kV5mYX7d6DmBc23d4vdtCYr3214bJWtmPw2W7VCoeQvLHL1yzvsZ4OFzIuMU_YlpKnmZzOdm3NO-pN4gNOrWmLO0VXmmneR7tyGllBvgg1AK36wkKfVHJ84VZCgPrOcWyzYktMhMpd14RGeUe7CvInsIyKJHnLu1IiwdWeqaneXnVzJYt1jgxzTv8Y4LC98Q8pY4S3Vqfbj0NPaVTuZiYJoyJx2ZZJFg_SR1Nd9Ah5SM9MJrWRiV3LINmn5kiZftRMUyW4Er5BuP0dD9qSmIJiNnOJ4TmVVlsnkw-f_IPr0sUf03BJlBRhBSZs7geEQfFePcqNHCWGhes1rxGztHyqTP9sKPVsGvLz5cddMD6XYvNwUVUMDLRWHmJL7Db92E4g5hwUduEMW9Ti5IyB0835LPvtao5zDUYdzMdp58O9xbbLr4-PDg-RgcrS_zm54sDkpnMfzN9hg-b0yD2EzLtNH9Ubl7MtVS4bfa9GElg |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3fb9MwELamIiFeEOPXCoMZBAIesi5xGicPCE2MamUwELCpb8FxnFFRJYU0Qvtv-Dv46_guccKCJsTLpKqq6nPq2pfzd_Hdd4w9cqkUJhxlB9BAOL6BgxIZL3KiBOA5FCqRNWX-28Ng_8h_PRvP1tivNheGwipbm1gb6rTQ9Ix8JChMHkjQC0aZDYt4vzd5sfzmUAUpOmlty2k0KnJgTn_AfSufT_ew1o89b_Lq08t9x1YYcDRw9goGyMjM942QSmqptK8DpTV8FG0SlahARkoAz3iw75lJNdAUhu9qoZNUCh0QERPM_yUpgKpwL8lZ5-zBjgSBTdUT0h1ZzdheFrnZJjrOkDJizmyFdkMYLBdFeR7a_Tto88wuOLnGrlr4yncbfVtnaya_ztatgSj5U8ti_ewG-9nwIvMi45SJCcua8q_zNDennPZS0gdOr2qF-UdXlae8i3rnNsyEehOFAFrxg4U6qRb4xKmaBPWZ59zywpacHihzVRch4RnlMSyaKD8SUuihFk7NDlt3pgp3N9nRhSzWLTbIMf0bjAOF4RvamDXekjRJRRR4aerqncyEfjhkTrsy8bJh_Yjroz8Jb6mZ6ZhWMrYrOWRbtHxxk7vaGY14N4SHSCeh4yF7WEsQ5UZOynuiqrKMp--O_0Po44ee0BMrlBVQBK1sHgWGQ1RePcnNniQMh-41b5CytX-ojP_cYujZKuD5zQ-6ZrooxenlpqgaGexYUYApud3oazeBmHOgad8dsrCnyZ0AMZ33W_L5l5rxHE47HI3xzp1_j2uLXYZNiN9MDw_usise4CdF9nhikw1W3ytzD_Bxldyv71POPl-0YfgNcCSI1Q |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Effect+of+impaired+kidney+function+on+outcomes+and+treatment+effects+of+oral+anticoagulant+regimes+in+patients+with+atrial+fibrillation+in+a+real-world+registry&rft.jtitle=PloS+one&rft.au=Salbach%2C+Christian&rft.au=Milles%2C+Barbara&rft.au=Hund%2C+Hauke&rft.au=Biener%2C+Moritz&rft.date=2024-09-23&rft.pub=Public+Library+of+Science&rft.eissn=1932-6203&rft.volume=19&rft.issue=9&rft_id=info:doi/10.1371%2Fjournal.pone.0310838&rft.externalDocID=3108572926 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1932-6203&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1932-6203&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1932-6203&client=summon |